TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...
The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.
Health and Me on MSN3d
FDA Approves TNKase To Treat Ischemic Strokes In AdultsIt is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, ...
Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...
According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...
THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic ...
Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...
Pharmaceutical Technology on MSN6d
Genentech wins FDA approval for second stroke treatmentGenentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback